Kardio Chlumec s.r.o.

Chlumec Nad Cidlinou Iv 11 trials 6 recruiting

11 Registered trials

6 Currently recruiting

Organisation

Kardio Chlumec s.r.o.

Location

Chlumec Nad Cidlinou Iv, Czechia

Identifier

ORG-100046104

Address

Nadrazni 783, 503 51, Czechia

Departments

#2108; Kardiologie
#3193:Kardiologie
2317: Kardiologie
2317:Kardiologie
3193: Kardiologie
Cardiology
Cardiology department
N/A

Clinical trials at this site (11)

Search interface

A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Unknown

2022-502779-40-99 Primary prevention of atherosclerotic cardiovascular di 5
An open-label extension (OLE) trial to evaluate long-term safety and tolerability of pelacarsen (TQJ230) Recruiting

2024-519870-38-00 Atherosclerotic cardiovascular disease (ASCVD) 5 2026-05-11
ZENITH: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk … Recruiting

2025-522960-34-00 Established cardiovascular disease 5 2026-02-09
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and … Recruiting

2024-516652-18-00 Atherosclerotic cardiovascular disease (ASCVD) and obes 5 2025-10-10
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatme… Recruiting

2023-508875-35-00 Heart condition 5 2025-09-01
A phase III, randomized, open-label, blinded endpoint, comparative trial of ferric derisomaltose versus no intravenous iron in iron-deficien… Recruiting

2024-519059-28-00 Chronic Heart Failure 5 2025-07-17
202301CPC Redefine-HF Recruiting

2023-508581-15-00 Heart condition 5 2024-10-08
A Study to Find Out How Safe and Well AZD0780 Works for Adults with High 'Bad' Cholesterol and with Heart- Stroke or Vascular Disease or at … Ended

2025-520521-21-00 Hyperlipidemia 5 2025-09-02
A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Ended

2022-502779-40-00 Primary prevention of atherosclerotic cardiovascular di 5 2023-09-04
A multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients wit… Ended

2023-508292-37-00 Cardiovascular Disease 5 2020-03-06
Study to understand if inclisiran is better than a placebo at lowering LDL-cholesterol,is safe and can have an impact on patient quality of … Ended

2024-511263-28-00 Hypercholesterolemia 6 2022-04-08